HIV treatment as prevention: Issues in economic evaluation

PLoS Medicine

Volumn 9, Issue 7, 2012, Pages

  Bärnighausen, Till ^a,b   Salomon, Joshua A ^a   Sangrujee, Nalinee ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; ECONOMIC DEVELOPMENT; ECONOMIC EVALUATION; HEALTH CARE POLICY; HEALTH PROGRAM; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MORTALITY; QUALITY OF LIFE; TREATMENT OUTCOME; VIRUS TRANSMISSION; COST; ECONOMICS; EVALUATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; REVIEW;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COSTS AND COST ANALYSIS; EVALUATION STUDIES AS TOPIC; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME;

EID: 84864482374     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001263     Document Type: Article

References (30)

1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
2. Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, et al. (2011) Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 9: 446-469.
3. Boily MC, Mâsse B, Alsallaq R, Padian NS, Eaton JW, et al. (2012) HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med 9: e1001250 doi:10.1371/journal.pmed.1001250.
4. Hontelez JA, de Vlas SJ, Tanser F, Bakker R, Bärnighausen T, et al. (2011) The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PLoS ONE 6: e21919 doi:10.1371/journal.pone.0021919.
5. Long EF, Brandeau ML, Owens DK, (2010) The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med 153: 778-789.
6. Vijayaraghavan A, Efrusy MB, Mazonson PD, Ebrahim O, Sanne IM, et al. (2007) Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr 46: 91-100.
7. Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, et al. (2012) HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 9: e1001245 doi:10.1371/journal.pmed.1001245.
8. Meyer-Rath G, Over M, (2012) HIV treatment as prevention: modelling the cost of antiretroviral treatment-state of the art and future directions. PLoS Med 9: e1001247 doi:10.1371/journal.pmed.1001247.
9. Bärnighausen T, Kyle M, Salomon JA, Waning B, (2011) Assessing the population health impact of market interventions to improve access to antiretroviral treatment. Health Policy Plan E-pub ahead of print. doi:10.1093/heapol/czr058.
10. Guinness L, Kumaranayake L, Hanson K, (2007) A cost function for HIV prevention services: is there a 'u'- shape? Cost Eff Resour Alloc 5: 13.
11. Guinness L, Kumaranayake L, Rajaraman B, Sankaranarayanan G, Vannela G, et al. (2005) Does scale matter? The costs of HIV-prevention interventions for commercial sex workers in India. Bull World Health Organ 83: 747-755.
12. Marseille E, Dandona L, Marshall N, Gaist P, Bautista-Arredondo S, et al. (2007) HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries. BMC Health Serv Res 7: 108.
13. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG, (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57.
14. Hallett TB, Gregson S, Dube S, Mapfeka ES, Mugurungi O, et al. (2011) Estimating the resources required in the roll-out of universal access to antiretroviral treatment in Zimbabwe. Sex Transm Infect 87: 621-628.
15. Nash D, Wu Y, Elul B, Hoos D, El Sadr W, (2011) Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries. AIDS 25: 1523-1533.
16. Lahuerta M, Hoffman S, Elul B, Wu Y, Gorrell Kulkarni S, et al. (2012) Change over time in CD4+ count and disease stage at entry into HIV care-findings from 9 sub-Saharan African countries [abstract]. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, Washington, US.
17. South African Department of Health (2010) HIV counselling and testing (HCT) policy guidelines Pretoria South African Department of Health.
18. Bärnighausen T, Tanser F, Dabis F, Newell M, (2012) Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa: the experimental evidence. Curr Opin HIV AIDS 11: 942-951.
19. Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, et al. (2011) Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis 11: 942-951.
20. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, et al. (2011) Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 8: e1001123 doi:10.1371/journal.pmed.1001123.
21. Sterne J, May M, Costagliola D, Egger M, Hogg R, et al. (2006) Early HAART associated with improved outcomes & fewer toxicities [abstract]. 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver, Colorado, US.
22. Lichtenstein K, Armon C, Buchacz K, Moorman A, Wood K, et al. (2006) Early, uninterrupted ART is associated with improved outcomes and fewer toxicities in the HIV outpatient study (HOPS) [abstract]. 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver, Colorado, US.
23. Armon C, Lichtenstein K, (2011) The associations among coping, nadir CD4+ T-cell count, and non-HIV-related variables with health-related quality of life among an ambulatory HIV-positive patient population. Qual Life Res E-pub ahead of print. doi:10.1007/s11136-011-0017-2.
24. Panel on Antiretroviral Guidelines for Adults and Adolescents (2012) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington (District of Columbia): US Department of Health and Human Services.
25. Thirumurthy H, Graff Zivin J, Goldstein MP, (2005) The economic impact of AIDS treatment: labor supply in western Kenya. J Hum Res 43: 511-552.
26. Rosen S, Ketlhapile M, Sanne I, Desilva MB, (2008) Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa. AIDS 22 (Suppl 1): S131-S139.
27. Larson BA, Fox MP, Rosen S, Bii M, Sigei C, et al. (2008) Early effects of antiretroviral therapy on work performance: preliminary results from a cohort study of Kenyan agricultural workers. AIDS 22: 421-425.
28. Bor J, Tanser F, Newell ML, Bärnighausen T, (2012) Nearly full employment recovery among HIV patients on antiretroviral therapy: evidence from a large population cohort. Health Aff (Millwood) In press.
29. Hontelez JA, Lurie MN, Newell ML, Bakker R, Tanser F, et al. (2011) Ageing with HIV in South Africa. AIDS 25: 1665-1667.
30. Hontelez JA, de Vlas SJ, Baltussen R, Bakker R, Tanser F, et al. (2012) The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa. AIDS In press.